MCID: BLD047
MIFTS: 39

Bladder Squamous Cell Carcinoma

Categories: Cancer diseases, Nephrological diseases, Skin diseases

Aliases & Classifications for Bladder Squamous Cell Carcinoma

MalaCards integrated aliases for Bladder Squamous Cell Carcinoma:

Name: Bladder Squamous Cell Carcinoma 12 15 17 74
Epidermoid Carcinoma of the Urinary Bladder 12
Squamous Cell Carcinoma of Bladder 12
Carcinoma Squamous Cell Bladder 56

Classifications:



External Ids:

Disease Ontology 12 DOID:3742
NCIt 51 C4031
UMLS 74 C0279681

Summaries for Bladder Squamous Cell Carcinoma

Disease Ontology : 12 A carcinoma of bladder that is manifested in squamous cells of the bladder.

MalaCards based summary : Bladder Squamous Cell Carcinoma, also known as epidermoid carcinoma of the urinary bladder, is related to squamous cell carcinoma and transitional cell carcinoma, and has symptoms including dysuria An important gene associated with Bladder Squamous Cell Carcinoma is CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Epirubicin and Fluorouracil have been mentioned in the context of this disorder. Affiliated tissues include lung, kidney and lymph node, and related phenotype is pigmentation.

Related Diseases for Bladder Squamous Cell Carcinoma

Diseases related to Bladder Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 130)
# Related Disease Score Top Affiliating Genes
1 squamous cell carcinoma 29.8 BRAF CDKN2A S100A7 TP53
2 transitional cell carcinoma 29.1 BRAF CDKN2A TP53 UPK2
3 ductal carcinoma in situ 10.1 S100A7 TP53
4 keratinizing squamous cell carcinoma 10.1 CDKN2A TP53
5 retroperitoneum carcinoma 10.1 CDKN2A UPK2
6 vulva squamous cell carcinoma 10.1 CDKN2A TP53
7 scrotal carcinoma 10.1 CDKN2A TP53
8 thyroid lymphoma 10.1 CDKN2A TP53
9 vulvar disease 10.1 CDKN2A TP53
10 nasal cavity adenocarcinoma 10.1 CDKN2A TP53
11 bartholin's gland disease 10.1 CDKN2A TP53
12 anal squamous cell carcinoma 10.1 CDKN2A TP53
13 megaesophagus 10.1 CDKN2A TP53
14 glycogen-rich clear cell breast carcinoma 10.1 CDKN2A TP53
15 gastric adenosquamous carcinoma 10.1 CDKN2A TP53
16 anogenital venereal wart 10.1 CDKN2A TP53
17 cervix uteri carcinoma in situ 10.1 CDKN2A TP53
18 uterus carcinoma in situ 10.1 CDKN2A TP53
19 oral leukoplakia 10.1 CDKN2A TP53
20 meningeal melanomatosis 10.1 CDKN2A TP53
21 suppressor of tumorigenicity 3 10.1 CDKN2A TP53
22 dedifferentiated liposarcoma 10.1 CDKN2A TP53
23 liposarcoma 10.1 CDKN2A TP53
24 endocervical adenocarcinoma 10.1 CDKN2A TP53
25 cervical adenocarcinoma 10.1 CDKN2A TP53
26 penile disease 10.1 CDKN2A TP53
27 cervix small cell carcinoma 10.1 CDKN2A TP53
28 small cell carcinoma 10.1 CDKN2A TP53
29 necrotizing sialometaplasia 10.1 CDKN2A TP53
30 verrucous carcinoma 10.1 CDKN2A TP53
31 basaloid squamous cell carcinoma 10.1 CDKN2A TP53
32 tongue disease 10.1 CDKN2A TP53
33 optic nerve neoplasm 10.1 CDKN2A TP53
34 juvenile pilocytic astrocytoma 10.1 CDKN2A TP53
35 tonsil cancer 10.1 CDKN2A TP53
36 vulva cancer 10.1 CDKN2A TP53
37 squamous cell papilloma 10.1 CDKN2A TP53
38 schistosomiasis 10.1
39 laryngeal disease 10.1 CDKN2A TP53
40 barrett's adenocarcinoma 10.1 CDKN2A TP53
41 oropharynx cancer 10.1 CDKN2A TP53
42 pharynx cancer 10.1 CDKN2A TP53
43 pancreatic ductal carcinoma 10.1 CDKN2A TP53
44 cervix carcinoma 10.1 CDKN2A TP53
45 skin squamous cell carcinoma 10.1 CDKN2A TP53
46 inverted papilloma 10.1 CDKN2A TP53
47 cellular schwannoma 10.1 CDKN2A TP53
48 penile cancer 10.1 CDKN2A TP53
49 in situ carcinoma 10.1 CDKN2A TP53
50 central nervous system lymphoma 10.0 CDKN2A TP53

Graphical network of the top 20 diseases related to Bladder Squamous Cell Carcinoma:



Diseases related to Bladder Squamous Cell Carcinoma

Symptoms & Phenotypes for Bladder Squamous Cell Carcinoma

UMLS symptoms related to Bladder Squamous Cell Carcinoma:


dysuria

MGI Mouse Phenotypes related to Bladder Squamous Cell Carcinoma:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 pigmentation MP:0001186 8.8 BRAF CDKN2A TP53

Drugs & Therapeutics for Bladder Squamous Cell Carcinoma

Drugs for Bladder Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 60)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Epirubicin Approved Phase 3 56420-45-2 41867
2
Fluorouracil Approved Phase 3 51-21-8 3385
3
BCG vaccine Investigational Phase 3
4 interferons Phase 3
5 Anti-Bacterial Agents Phase 3,Phase 1
6 Antiviral Agents Phase 3,Phase 2
7 Vaccines Phase 3,Phase 1
8 Anti-Infective Agents Phase 3,Phase 2,Phase 1
9 Adjuvants, Immunologic Phase 3
10 Interferon-alpha Phase 3
11 Mitomycins Phase 3
12 Immunologic Factors Phase 3,Phase 2,Phase 1
13 Nucleic Acid Synthesis Inhibitors Phase 3
14 Topoisomerase Inhibitors Phase 3,Phase 2
15 Alkylating Agents Phase 3,Phase 2
16 Antibiotics, Antitubercular Phase 3
17 Pharmaceutical Solutions Phase 3
18 Antimetabolites, Antineoplastic Phase 3,Phase 2
19 Immunosuppressive Agents Phase 3,Phase 2
20 Antimetabolites Phase 3,Phase 2
21
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
22
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
23
Carboplatin Approved Phase 2 41575-94-4 38904 10339178 498142
24
Gemcitabine Approved Phase 2 95058-81-4 60750
25
leucovorin Approved Phase 2 58-05-9 6006 143
26
Cisplatin Approved Phase 2 15663-27-1 441203 84093 2767
27
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
28
Ifosfamide Approved Phase 2 3778-73-2 3690
29
Durvalumab Approved, Investigational Phase 2 1428935-60-7
30
nivolumab Approved Phase 2,Phase 1 946414-94-4
31
Ipilimumab Approved Phase 2,Phase 1 477202-00-9
32
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
33
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
34 Piritrexim Investigational Phase 2 72732-56-0
35
Camptothecin Experimental Phase 2 7689-03-4
36
Rubitecan Investigational Phase 2 91421-42-0
37
Tremelimumab Investigational Phase 2 745013-59-6
38 Antineoplastic Agents, Immunological Phase 2,Phase 1
39 Antimitotic Agents Phase 2
40 Albumin-Bound Paclitaxel Phase 2
41 Antineoplastic Agents, Phytogenic Phase 2
42 Folic Acid Antagonists Phase 2
43 Folate Phase 2
44 Vitamin B9 Phase 2
45 Vitamin B Complex Phase 2
46 topoisomerase I inhibitors Phase 2
47 Antineoplastic Agents, Alkylating Phase 2
48
Isophosphamide mustard Phase 2 0
49 Immunoglobulins Phase 2,Phase 1
50 Antibodies, Monoclonal Phase 2,Phase 1

Interventional clinical trials:

(show all 20)
# Name Status NCT ID Phase Drugs
1 Hyperthermia and Mitomycin C, Bacillus Calmette-Guerin, or Standard Therapy as Second-Line Therapy in Treating Patients With Recurrent Bladder Cancer Unknown status NCT01094964 Phase 3 epirubicin hydrochloride;mitomycin C
2 Radiation Therapy With or Without Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer Completed NCT00024349 Phase 3 fluorouracil;mitomycin C
3 Standard Surgery or Minimal-Access Surgery in Treating Patients With Bladder Cancer Unknown status NCT01196403 Phase 2
4 Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer Completed NCT00005831 Phase 2 paclitaxel;carboplatin;gemcitabine hydrochloride
5 VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium Completed NCT00407485 Phase 2
6 Piritrexim in Treating Patients With Advanced Cancer of the Urinary Tract Completed NCT00002914 Phase 2 piritrexim
7 S0121, Neoadjuvant Carboplatin, Paclitaxel, and Gemcitabine Followed by Cisplatin and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Carcinoma of the Urothelium Completed NCT00055835 Phase 2 carboplatin;cisplatin;gemcitabine hydrochloride;paclitaxel
8 Nitrocamptothecin in Treating Patients With Metastatic Cancer of the Urinary Tract Completed NCT00006026 Phase 2 rubitecan
9 Combination Chemotherapy in Patients With Advanced Urinary Tract Cancer Completed NCT00002684 Phase 2 cisplatin;ifosfamide;paclitaxel
10 Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract Recruiting NCT03430895 Phase 2 durvalumab and tremelimumab
11 Cabozantinib S-Malate, Nivolumab, and Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors Not yet recruiting NCT03866382 Phase 2 Cabozantinib;Cabozantinib S-malate
12 Gemcitabine Hydrochloride and Cisplatin Before Surgery in Treating Patients With Muscle Invasive Bladder Cancer Terminated NCT01611662 Phase 2 gemcitabine hydrochloride;cisplatin
13 Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium Terminated NCT00112905 Phase 2 sorafenib tosylate
14 S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract Terminated NCT00022633 Phase 2 gemcitabine hydrochloride;paclitaxel
15 3-Dimensional Conformal Radiation Therapy in Treating Patients With Bladder Cancer Who Have Undergone Transurethral Resection of the Bladder Unknown status NCT01124682 Phase 1
16 Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous Treatment Completed NCT00016237 Phase 1
17 Cabozantinib-s-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors Recruiting NCT02496208 Phase 1 Cabozantinib S-malate
18 Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy Terminated NCT00072137 Phase 1
19 OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer Completed NCT00900302
20 Adjuvant Radiation for High Risk Bladder Cancer Recruiting NCT01954173 Not Applicable

Search NIH Clinical Center for Bladder Squamous Cell Carcinoma

Genetic Tests for Bladder Squamous Cell Carcinoma

Anatomical Context for Bladder Squamous Cell Carcinoma

MalaCards organs/tissues related to Bladder Squamous Cell Carcinoma:

42
Lung, Kidney, Lymph Node

Publications for Bladder Squamous Cell Carcinoma

Articles related to Bladder Squamous Cell Carcinoma:

(show all 16)
# Title Authors Year
1
Frequent PD-L1 Protein Expression and Molecular Correlates in Urinary Bladder Squamous Cell Carcinoma. ( 29980330 )
2018
2
Lung Involvement in Chronic Schistosomiasis with Bladder Squamous Cell Carcinoma. ( 30460893 )
2018
3
Risk factors for development of primary bladder squamous cell carcinoma. ( 27869492 )
2016
4
Bladder squamous cell carcinoma in pregnancy. ( 26467844 )
2015
5
Vesicoenteric fistula due to bladder squamous cell carcinoma. ( 25045451 )
2014
6
Radiation treatment of bladder squamous cell carcinoma in a patient with spina bifida: A case report. ( 22709884 )
2012
7
Urinary schistosomiasis with simultaneous bladder squamous cell carcinoma and transitional cell carcinoma. ( 23109968 )
2012
8
p16 expression is not associated with human papillomavirus in urinary bladder squamous cell carcinoma. ( 22684221 )
2012
9
Enterovesical fistula caused by a bladder squamous cell carcinoma. ( 19725163 )
2009
10
Bladder squamous cell carcinoma. ( 15143234 )
2004
11
Bladder squamous cell carcinoma biomarkers derived from proteomics. ( 10892722 )
2000
12
Uroplakin II gene is expressed in transitional cell carcinoma but not in bilharzial bladder squamous cell carcinoma: alternative pathways of bladder epithelial differentiation and tumor formation. ( 9515818 )
1998
13
Enhanced tumorigenicity of rat bladder squamous cell carcinoma cells after abrogation of gap junctional intercellular communication. ( 9685850 )
1998
14
Bladder squamous cell carcinoma with human papilloma virus type 6 [HPV 6]. ( 8749958 )
1995
15
UNME/K1: an IgG2a monoclonal antibody specific to cytokeratin of human urinary bladder squamous cell carcinoma. ( 1712997 )
1991
16
Dramatic palliation for painful, fixed bladder squamous cell carcinoma with 5-fluorouracil infusion. ( 71361 )
1977

Variations for Bladder Squamous Cell Carcinoma

Expression for Bladder Squamous Cell Carcinoma

Search GEO for disease gene expression data for Bladder Squamous Cell Carcinoma.

Pathways for Bladder Squamous Cell Carcinoma

GO Terms for Bladder Squamous Cell Carcinoma

Biological processes related to Bladder Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Ras protein signal transduction GO:0007265 9.26 CDKN2A TP53
2 cellular response to drug GO:0035690 9.16 BRAF TP53
3 positive regulation of gene expression GO:0010628 9.13 BRAF CDKN2A TP53
4 replicative senescence GO:0090399 8.62 CDKN2A TP53

Molecular functions related to Bladder Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 disordered domain specific binding GO:0097718 8.62 CDKN2A TP53

Sources for Bladder Squamous Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....